Skip to main content
Home
FULL MENU Close Menu
Home
Home

Sara Freeman

News

Cardiovascular risk score multipliers suggested for rheumatic diseases

Author:
Sara Freeman
Publish date: December 21, 2022

Guidelines could tailor cardiovascular risk scores by using a multiplier of 2.5 for systemic sclerosis, 2.0 for lupus, and 1.5 for any other...

  • Read More

News

RA risk raised by work-related inhaled agents

Author:
Sara Freeman
Publish date: December 15, 2022

Exposure to detergents, dusts, and other chemicals in the workplace could be putting genetically susceptible people at risk of rheumatoid...

  • Read More

News

Gestational hypertension-diabetes combo signals CVD risk

Author:
Sara Freeman
Publish date: December 2, 2022

Having both hypertensive disorders and diabetes while pregnant ups later cardiovascular risk, suggesting greater care is needed when these...

  • Read More

News

Rituximab raises remission rate in granulomatosis with polyangiitis

Author:
Sara Freeman
Publish date: November 30, 2022

Remission at 6 months was recorded in 73.1% of rituximab-treated patients and 40.1% of cyclophosphamide-treated patients in a multicenter target...

  • Read More

News

52-week data show lebrikizumab atopic dermatitis effects maintained

Author:
Sara Freeman
Publish date: October 5, 2022

ADvocate1 and ADvocate2 are two of several phase 3 trials evaluating the efficacy and safety of lebrikizumab for the treatment of atopic...

  • Read More

News

Ruxolitinib repigments many vitiligo-affected body areas

Author:
Sara Freeman
Publish date: October 5, 2022

Ruxolitinib is a Janus kinase 1/2 inhibitor that has been available for the treatment for atopic dermatitis for more than a year.

  • Read More

News

BREEZE-AD-PEDS: First data for baricitinib in childhood eczema reported

Author:
Sara Freeman
Publish date: October 4, 2022

Treatment with the oral JAK inhibitor was significantly more effective than placebo only with the highest dose evaluated.

  • Read More

News

Alopecia areata: Positive results reported for two investigational JAK inhibitors

Author:
Sara Freeman
Publish date: September 30, 2022

“This is truly transformative therapy,” one of the investigators, Brett King, MD, PhD, said.

  • Read More

News

Study identifies skin biomarkers that predict newborn eczema risk

Author:
Sara Freeman
Publish date: September 30, 2022

"We are able to identify predictive immune biomarkers of atopic dermatitis using a noninvasive method," the investigator said.

  • Read More

News

Ezetimibe-statin combo lowers liver fat in open-label trial

Author:
Sara Freeman
Publish date: September 30, 2022

A significant 5.8% decrease in hepatic steatosis was seen after 24 weeks’ treatment with ezetimibe and rosuvastatin comparing baseline with end of...

  • Read More

News

Early age at hysterectomy ups type 2 diabetes risk

Author:
Sara Freeman
Publish date: September 23, 2022

Having a hysterectomy appears to increase the risk of incident type 2 diabetes, particularly in younger women, and if the ovaries are removed at...

  • Read More

News

Mothers’ diabetes linked to ADHD in their children

Author:
Sara Freeman
Publish date: September 22, 2022

A small increased risk of ADHD in children born to mothers with diabetes, including pregestational diabetes and gestational diabetes, has been...

  • Read More

News

Apremilast alleviates severe psoriasis in some children, data show

Author:
Sara Freeman
Publish date: September 20, 2022

“In this randomized, placebo-controlled trial, oral apremilast demonstrated effectiveness and was well tolerated.”

  • Read More

News

Hope shines bright for hidradenitis suppurativa treatments

Author:
Sara Freeman
Publish date: September 19, 2022

Research into HS is "an incredibly active field at this moment," said Alexa B. Kimball, MD, MPH.

  • Read More

News

Experts express caution over
type 2 diabetes/tea-drinking claim

Author:
Sara Freeman
Publish date: September 17, 2022

Drinking four cups of tea a day was linked to a 17% lower risk for developing type 2 diabetes in a study, but experts warn these data are...

  • Read More

Pages

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • …
  • last »

Privacy Policy

Terms of Use

Editorial Policy

Cookie Policy

Ad Policy

Medscape Customer Support

Frequently Asked Questions

 

Advertise with MDedge

See more with MDedge! See our Other Publications

MDedge: Keeping You Informed. Saving You Time.

Copyright  © 2023 Frontline Medical Communications Inc., Newark, NJ, USA. All rights reserved. Unauthorized use prohibited. The information provided is for educational purposes only. Use of this Web site is subject to the medical disclaimer.

Close